Pharmaceutical manufacturers of Amphetamine

Sun Pharma is a global, comprehensive, specialized pharmaceutical company with production facilities for API and FDF in India, the United States, Latin America, and Europe. It produces and sells a wide range of pharmaceutical formulations as branded generics and generic drugs in India, the US, and various other global markets. It is supported by 2 advanced R&D Centers with a team of over 600 scientists for projects in Chemical Synthesis, Clinical Research, and formulation development. Sun is a frontrunner in specific therapy areas and possesses robust expertise in product development, process chemistry, and manufacturing.

For more than three decades, we have been providing support to the pharmaceutical and biopharmaceutical sectors in the development of medications. Our aim is to aid our clients in the creation and introduction of new drugs to the market, ultimately enhancing the well-being of patients globally. We are dedicated to assisting our partners in producing and manufacturing intricate and demanding compounds, highly active ingredients, and pioneering advancements in vitamin, healthcare, and industrial products with the goal of making the world a better place.

Siegfried serves as your favored associate for comprehensive integrated pharmaceutical ingredient and drug product services with manufacturing capabilities globally. Our expertise is crucial for your venture throughout the entire lifespan. Our enthusiasm lies in creating and producing formulations. It is extraordinary for a provider of development and manufacturing services to possess such a blend of inherent technical expertise and knowledge. Pharmaceutical ingredient services entail Tailored Development and Outsourced Manufacturing for both active pharmaceutical ingredients (API) and intermediates, along with our own range of API (opiates and other regulated substances) and documentation featuring independent patented technologies. Clients utilizing our drug product services benefit from a wealth of inherited expertise in intricate oral drug delivery systems, including sterile filling, backed by in-house development, customer development and manufacturing, and a wide array of completed dosage form products. Enhancing chemical processes and formulations is our area of specialization. We collaborate closely with clients to innovate and enhance chemical processes, thus providing additional benefits and value. Siegfried operates at 11 locations globally, spanning both the Eastern and Western Hemispheres, with multi-purpose cGMP chemical manufacturing facilities in Zofingen, Switzerland; Pennsville, New Jersey, USA; Nantong, China; Minden, Germany; Saint-Vulbas, France; Evionnaz, Switzerland; and sites for manufacturing drug products in Zofingen, Switzerland; Malta; Hameln, Germany, Irvine, USA; Barberà del Vallès, Spain and El Masnou, Spain. Count on Siegfried as your preferred partner for more opportunities.

Veranova boasts over 50 years of expertise and is a frontrunner in the creation and fabrication of intricate and specialized APIs for the pharmaceutical and biotech sectors. It was previously a segment of Johnson Matthey, specializing in intricate and regulated chemical processes. The company delivers customized services throughout all phases of drug development and is split into Generics and Originators. It possesses a variety of development technologies and areas of expertise, along with a cooperative approach to API manufacturing and procedures.

Cambrex stands as a prominent global contract development and manufacturing organization (CDMO) delivering comprehensive analytical and IND enabling services, along with drug substance development and manufacturing throughout the entire drug lifecycle. Boasting 40 years of expertise and a workforce of 2,000 professionals catering to international clients from North America and Europe, Cambrex is a reliable ally in both the branded and generic markets for API development and manufacturing. The company provides a variety of specialized drug substance technologies and capabilities.

MNK’s Specialty Generics division provides a wide variety of high-quality generic medications, focusing on pain relief, addiction treatment, and ADHD, as well as a comprehensive range of active pharmaceutical ingredients (APIs), such as acetaminophen/paracetamol, DEA scheduled compounds, and stearates. We run the largest API facility in the United States. Discover the range of excipients available from Mallinckrodt Pharmaceuticals for use in pharmaceutical drug delivery systems (DDS).

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Axyntis Group, established in 2007, is the foremost independent multi-location entity in the field of fine chemicals in France, generating an annual revenue of €90 million. Axyntis has evolved into a significant manufacturer of APIs in France through acquisitions and collaborations. It encompasses two sectors (colorants and fine chemicals) and emphasizes diversification and pioneering initiatives. The company operates three cGMP facilities in France, two of which are approved by the FDA. It offers CDMO services to partners for their API or advanced intermediate projects, from the initial development phase to the commercial stage, inclusive of preparative chromatography (Kyrapharm subsidiary). Additionally, it markets exclusive APIs.

Ashland provides a diverse range of components for formulating effective pharmaceutical excipients. Our collection of cellulose-based polymers (HPMC, HPC, CMC, HEC) is expanding, and we are enhancing our excipient options for injectables/biologics, with the potential for customization, and emphasizing on film coatings. Our pharmaceutical portfolio encompasses ingredients for oral solid dosage, liquid dosage, controlled release functionality, coatings, disintegrants, binders, and now, injectables, positioning it as the core strength of Ashland.

Chr. Olesen Group operates as a global consortium of partner-led distribution and production firms. Chr. Olesen focuses on distributing ingredients and API’s across four distinct sectors: Feed, Food, Pharma, and Vet Pharma. The manufacturing arm of the group, Chr. Olesen Synthesis, is headquartered in Denmark and specializes in API's and intermediates, with particular emphasis on controlled substances such as Buprenorphine HCL, Buprenorphine base, and Buprenorphine intermediates, along with Dexamphetamine sulphate, Hydromorphone, Terbinafine, and Tolfenamic acid. Established in 1885, Chr. Olesen Group is presently under the management of the fourth generation.